Heart Failure

Introduction to Heart Failure

• Heart failure is a complex clinical syndrome characterized by the heart's inability to pump blood effectively, resulting in symptoms of dyspnea, fatigue, and fluid retention that can lead to pulmonary congestion and peripheral edema, as described by the American College of Cardiology and the European Heart Journal 1, 2
• The American Heart Association notes that increased pressures in heart failure result primarily from structural and functional cardiac abnormalities that impair the heart's ability to fill with or eject blood, leading to elevated ventricular filling pressures, pulmonary congestion, and systemic fluid retention 3

Causes of Heart Failure

• Coronary artery disease is the most common cause of heart failure, particularly in younger patients, leading to myocardial infarction and chronic ischemic heart disease, according to the American College of Cardiology 1
• Valvular heart disease, particularly mitral and aortic valve disorders, is a significant contributor to heart failure, as stated by the American College of Cardiology 4
• Congenital heart disease, which includes structural abnormalities present from birth, is also a cause of heart failure, as noted by the American College of Cardiology 1
• Infectious causes of heart failure include myocarditis, Chagas disease, and other bacterial or parasitic infections, as reported by the American College of Cardiology 1
• Toxic exposures, such as alcohol abuse, chemotherapeutic agents, mediastinal irradiation, and illicit drugs, can also lead to heart failure, according to the American College of Cardiology 1
• Metabolic disorders, including thyroid disorders, pheochromocytoma, and diabetes mellitus, can contribute to heart failure, as stated by the American College of Cardiology 1
• Systemic diseases, such as collagen vascular diseases, amyloidosis, and sarcoidosis, are also associated with heart failure, as noted by the American College of Cardiology 1 and 4
• Hypertension leads to left ventricular hypertrophy, increased afterload, and progressive myocardial dysfunction, as reported by the American College of Cardiology 1

Classification of Heart Failure

• Heart failure can be classified based on Ejection Fraction, with categories including Heart Failure with Reduced Ejection Fraction (HFrEF): EF ≤40%, Heart Failure with Mid-range Ejection Fraction (HFmrEF): EF 41-49%, and Heart Failure with Preserved Ejection Fraction (HFpEF): EF ≥50%, as defined by the European Heart Journal 5, 2
• The American College of Cardiology/American Heart Association classifies heart failure in stages, including Stage A: high risk for HF but without structural heart disease or symptoms, Stage B: structural heart disease but without signs or symptoms of HF, Stage C: structural heart disease with prior or current symptoms of HF, and Stage D: refractory HF requiring specialized interventions 1
• Heart failure can also be classified based on functional capacity using the New York Heart Association classification:

5

Pathophysiology of Heart Failure

• Systolic dysfunction is characterized by reduced contractility, leading to decreased ejection fraction, increased end-systolic and end-diastolic volumes, and elevated left ventricular end-diastolic pressure (LVEDP) due to incomplete emptying 3
• Diastolic dysfunction is marked by impaired active relaxation and increased passive stiffness due to myocardial fibrosis, ventricular hypertrophy, and altered extracellular matrix composition, resulting in elevated filling pressures even with normal ejection fraction 6
• Cardiac remodeling includes chamber dilatation, hypertrophy, increased sphericity, and myocyte hypertrophy, as well as enhanced synthesis and deposition of extracellular matrix proteins and progressive accumulation of myocardial fibrosis 3
• Neurohormonal activation, including adrenergic and renin-angiotensin-aldosterone systems, endothelin, vasopressin, and inflammatory mediators, plays a crucial role in heart failure, as reported by Circulation Research 3

Risk Factors and Prevention

• Family history, with up to 30% of idiopathic dilated cardiomyopathy cases being familial, is a risk factor for heart failure, according to the American College of Cardiology 1
• Certain medications, including NSAIDs, COX-2 inhibitors, class I antiarrhythmics, and corticosteroids, can precipitate or worsen heart failure, as reported by the European Heart Journal 7
• Lifestyle factors, such as smoking, excessive alcohol consumption, and obesity, can also contribute to heart failure, as stated by the American College of Cardiology 1
• The European Society of Cardiology recommends determining the underlying etiology of heart failure, identifying precipitating factors, assessing severity, and targeting treatment at both the underlying cause and the heart failure syndrome itself, with a strength of evidence based on expert opinion 7
• The European Society of Cardiology also emphasizes the importance of prevention and control of diseases leading to cardiac dysfunction and heart failure, early intervention, and lifestyle modifications, including sodium restriction, fluid control, and moderate alcohol intake, with a strength of evidence based on expert opinion 7

Epidemiology of Heart Failure

• Heart failure affects approximately 1-2% of adults in developed countries, with prevalence increasing to ≥10% among people >70 years of age, and is more common in men at younger ages, with equal prevalence in elderly, as reported by the European Heart Journal 5, 2
• Comorbidities, such as diabetes, obesity, kidney disease, and COPD, can worsen heart failure progression, as stated by the American College of Cardiology 1

Treatment of Heart Failure

• Treatment strategies include pharmacological therapy, such as diuretics, ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, as well as device therapies, such as implantable cardioverter-defibrillators and cardiac resynchronization therapy, and advanced therapies, such as heart transplantation and ventricular assist devices, as recommended by the American College of Cardiology 1
• Early recognition and treatment are essential to improve outcomes, and treatment should target both symptom relief and disease modification, with regular monitoring for disease progression and treatment response, and patient education about medication adherence, diet, and self-monitoring, as emphasized by the American College of Cardiology 1
• The European Society of Cardiology recommends therapies targeting neurohormonal activation, such as ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, to help reduce pressures and improve outcomes in heart failure, although the specific details are not provided in the article 6